Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
Labcorp entered a definitive agreement to acquire Myriad Genetics' Prenatal Health testing business for $210 million in cash plus the value of inventory at closing. The acquired portfolio includes the Prequel, Foresight, SneakPeek and FirstGene tests, used by over 600,000 patients in the last twelve months. Labcorp expects the deal to add approximately $160 million of revenue in year one and be slightly accretive to adjusted earnings.
Key figures
- Deal Value Usd
- 210000000
- Expected close
- by early 2027
- Expected year1 revenue add
- 160000000
- Trailing twelve month patients
- 600000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.